May 30, 2025

Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators.

Bastian Schilling, Director at the Dermatology Clinic of Frankfurt University, was one of the dermatologists participating in the current study.
(C) private

In a two-phase study, 76 dermatologists each assessed 16 images (melanomas and benign moles, known as nevi) taken with a dermatoscope, an illuminated magnifying glass, first using standard AI and then with an explainable AI solution. Explainable AI, or XAI for short, combines AI predictions with textual and image-based explanations based on established dermatoscopic features. Eye-tracking measurements were used to record how long and how intensively the participants looked at certain image regions and explanations.

Eye tracking as an objectification method

Analysis of gaze patterns showed that difficult cases were associated with an increased number of fixations – an objective indicator of cognitive effort. In the XAI phase, this effort decreased in challenging cases compared to standard AI, indicating a relieving effect of the explanations provided.

“Our results show that explainable AI not only increases diagnostic confidence, but can also support endurance in difficult cases in clinical practice,” explains Titus J. Brinker, senior author of the current study. “Especially with a high caseload and complex lesions, explainable artificial intelligence can help prevent fatigue and thus minimize potential sources of error.”

Follow-up studies are planned to investigate the long-term impact on workload and diagnostic quality in real-world clinical settings.


Chanda, T., Haggenmueller, S., Bucher, TC. et al. Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking study.
Nature Communications, 2025, https://doi.org/10.1038/s41467-025-59532-5

Our latest News

discover more
China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]

aimed analytics GmbH highlighted in deutsche-startups.de

aimed analytics GmbH highlighted in deutsche-startups.de

5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp